LOGIN
ID
PW
MemberShip
2025-07-19 07:57
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
More treatment options for PNH¡¦entry of 'Piasky' imminent
by
Eo, Yun-Ho
Jun 4, 2025 06:19am
The entry 'Piasky,' a new PNH drug, into the Korean market is imminent. According to industry sources, Roche Korea's Piasky (crovalimab), a treatment for paroxysmal nocturnal hemoglobinuria (PNH), is undergoing final review for approval by the Ministry of Food and Drug Safety (MFDS). It is expected to be officially approved in the second
Company
UCB Korea launches psoriasis drug Bimzelx with reimb
by
Whang, byung-woo
Jun 4, 2025 06:18am
On June 2, UCB Korea (CEO Sujin Hwang) announced that its psoriasis treatment Bimzelx (bimekizumab) was launched on June 1 with reimbursement coverage under the national health insurance system. In line with the Ministry of Health and Welfare (MOHW) notification, Bimzelx is reimbursed as a treatment for moderate-to-severe plaque psoriasis
Company
"U.S. MFN drug policy will impact KOR's new drug companies"
by
Kim, Jin-Gu
Jun 4, 2025 06:17am
Analysis suggests that the Korean pharmaceutical and biotech industry may be significantly impacted if the U.S. government institutes a 'most-favored-nation (MFN)' policy on drug prices. Sejin Lee, CEO of Acadia Pharmaceuticals, presented the potential impact of U.S. drug price policy changes on the Korean pharmaceutical industry during the '
Company
Multiple myeloma drug Elrexfio seeks reimb again in KOR
by
Eo, Yun-Ho
Jun 2, 2025 05:51am
The new multiple myeloma drug Elrexfio is again seeking insurance reimbursement coverage in Korea. Pfizer Korea recently submitted a reimbursement application for Elrexfio (elranatamab) and is aiming to receive the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee review. Following its rejection by
Company
Vocabria+Rekambys for HIV lands in more hospitals in KOR
by
Eo, Yun-Ho
Jun 2, 2025 05:51am
More general hospitals are securing prescriptions for the long-acting HIV treatment combination therapy Vocabria+Rekambys. According to industry sources, the combination therapy of GSK Korea¡¯s Vocabria (cabotegravir) and Janssen Korea¡¯s Rekambys (rilpivirine) has recently been approved by the drug committees (DCs) of several major hospi
Company
Samsung Bioepis¡¯ Xgeva biosimilar approved in KOR
by
Chon, Seung-Hyun
Jun 2, 2025 05:50am
Samsung Bioepis announced on the 30th that it has received approval from the Ministry of Food and Drug Safety for its biosimilar Xbryk, a bone disease treatment. Xbryk, which contains denosumab, is used to prevent skeletal complications in cancer patients and treat tumor diseases such as giant cell tumor of bone. Prolia, which contains t
Company
Janssen attempts Darzalex¡¯s reimb for AL amyloidosis in KOR
by
Eo, Yun-Ho
May 30, 2025 05:58am
Darzalex, which has been expanding its insurance coverage to multiple myeloma, is now seeking to receive reimbursement for amyloidosis in Korea. According to Dailypharm coverage, Janssen Korea recently applied for reimbursement expansion of Darzalex SC (daratumumab) in combination with cyclophosphamide, bortezomib, and dexamethasone (CyBo
Company
Galderma challenges the atopic dermatitis market in KOR
by
Whang, byung-woo
May 29, 2025 05:52am
Galderma is challenging the Korean market for atopic dermatitis treatment with its first biologic, 'Nemluvio (nemolizumab).' Given the market's already competitive nature, Galderma is likely to secure a market presence with the drug's mechanistic differentiation, convenient administration, and expanded indication. Galderma Korea submitt
Company
BeiGene announces name change to 'BeOne Medicines'
by
Whang, byung-woo
May 29, 2025 05:51am
BeiGene announced on May 28 that it has relaunched as BeOne Medicines Ltd., a company registered in Switzerland, along with its new name. This name change marks a significant milestone for the company and is part of a broader effort to strengthen its identity within the global biopharmaceutical industry. BeiGene Korea, the domestic entity,
Company
Global expansion in sight for organoid leader CellArtgen
by
Whang, byung-woo
May 28, 2025 05:58am
Organoids, miniature organs composed of cells, are emerging as a technology to replace animal testing in the pharmaceutical and biotechnology industry.&8232; With the field of organoids gaining attention, the activities of CellArtgen, which was founded by Cho Seung-woo, a leading expert in the field and professor at Yonsei University's Depar
1
2
3
4
5
6
7
8
9
10
>